HLA-A*0201 | B2M & HIV Gag

Product Inquiry

HLA-A*0201 | B2M & HIV Gag Background

HIV (human immunodeficiency virus) is a virus that attacks the body’s immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome). It can be transmitted via the exchange of a variety of body fluids from infected people, such as blood, breast milk, semen and vaginal secretions, And from a mother to her child during pregnancy and delivery. This disease can be managed by treatment regimens composed of a combination of antiretroviral (ARV) drugs. The Human HLA-A*0201 HIV (SLYNTVATL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and SLYNTVATL peptide of the HIV.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
KLS-2031KLS-2031Phase 2 ClinicalKolon Life Science. IncRadiculopathy
Details
NGM-386NGM-386Phase 1 ClinicalNgm Biopharmaceuticals IncObesity
Details
NGM-395NGM-395Phase 1 ClinicalNgm Biopharmaceuticals IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
  • Product Inquiry
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland